Immune Pharmaceuticals(美国)
Immune Pharmaceuticals
ImmunePharmaceuticalswww.immunepharmaceuticals.com关注于治疗炎症疾病与癌症的抗体治疗平台ImmunePharmaceuticalsInc.(NASDAQOMXStockholmExchange:IMNP;OTCQX:IMNP,formerlyEPCTD)appliesapersonalizedapproachtotreatment,developi
ngnovel,highlytargetedantibodytherapeuticstoimprovethelivesofpatientswithinflammatorydiseasesandcancer.TheCompany'sleadproductcandidate,bertilimumab,isenteringPhaseIIclinicalstudiesformoderate-to-severeulcerativecolitisandbullouspemphigoid,withadditionalstudiesplannedforCrohn'sdiseaseandsevereasthma.TheCompanyisevaluatingtheuseofitsNanomAb®platform,asecondgenerationantibodydrugconjugatetechnology,withchemotherapeuticsinordertoenhancetheirsafetyandefficacyprofilesbydeliveringthemedicinesdirectlytocancercells.TheCompany'sgrowingoncologypipelinealsoincludesproprietaryantibodiesand,clinical-stagesmallmoleculesthathavebeenshownactivityinavarie